Fusion Pharmaceuticals Long Term Debt

Fusion Pharmaceuticals (FUSN) currently reports a long-term debt of $50M as of March 2024. That compares with $45M in the prior-year period — up 9.4% year over year. Use the charts on this page to explore Fusion Pharmaceuticals's long-term debt history and peer comparisons.

Fusion Pharmaceuticals's long-term debt increased from $45M to $50M — a 9.4% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fusion Pharmaceuticals reported $50M in long-term debt as of March 2024. That compares with $45M in the prior-year period — up 9.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $50M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Fusion Pharmaceuticals, and consider following FUSN for alerts when major investors trade the stock.

Fusion Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $50M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FUSN with unrelated industries.